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Abstract
Introduction: ECRG4/C2ORF40 is a potential tumor suppressor gene (TSG) recently identified in esophageal carcinoma. Its
expression, gene copy number and prognostic value have never been explored in breast cancer.
Methods: Using DNA microarray and array-based comparative genomic hybridization (aCGH), we examined ECRG4 mRNA
expression and copy number alterations in 353 invasive breast cancer samples and normal breast (NB) samples. A meta-
analysis was done on a large public retrospective gene expression dataset (n=1,387) in search of correlations between
ECRG4 expression and histo-clinical features including survival.
Results: ECRG4 was underexpressed in 94.3% of cancers when compared to NB. aCGH data revealed ECRG4 loss in 18% of
tumors, suggesting that DNA loss is not the main mechanism of underexpression. Meta-analysis showed that ECRG4
expression was significantly higher in tumors displaying earlier stage, smaller size, negative axillary lymph node status, lower
grade, and normal-like subtype. Higher expression was also associated with disease-free survival (DFS; HR=0.84 [0.76–0.92],
p=0.0002) and overall survival (OS; HR=0.72 [0.63–0.83], p=5.0E-06). In multivariate analysis including the other histo-
clinical prognostic features, ECRG4 expression remained the only prognostic factor for DFS and OS.
Conclusions: Our data suggest that ECRG4 is a candidate TSG in breast cancer, the expression of which may help improve
the prognostication. If functional analyses confirm this TSG role, restoring ECRG4 expression in the tumor may represent a
promising therapeutic approach.
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Introduction
Breast cancer is the most frequent and deadly cancer in women
in Western countries. Despite the mass screening and multidisci-
plinary therapeutic progresses, a substantial number of patients
(,25%) die from metastatic disease. Breast cancer is a complex
disease characterized by the accumulation of multiple molecular
alterations, genetic and epigenetic, which disturb the expression of
genes controlling critical regulatory processes. Efforts have been
directed at the identification of genes that play important roles in
mammary oncogenesis and metastatic processes and that could
represent new therapeutic and/or prognostic targets. Key genes
have been identified, including oncogenes encoding hormone
receptors (ER and PR) and tyrosine kinase receptors (ERBB2,
EGFR), and tumor suppressor genes (TSG) such as TP53, BRCA1,
and BRCA2. However, our molecular understandings of breast
cancer, together with clinical benefits for patients, remain limited.
Esophageal cancer-related gene 4 (ECRG4), officially called
C2ORF40, was cloned and identifiedf r o mn o r m a le s o p h a g e a l
epithelium [1]. It is localized in 2q12.2. The encoded protein
(augurin) is a secretory molecule produced in endocrine tissues
such as pituitary gland, adrenal gland and choroid plexus [2]. Its
actions consist in cerebrospinal fluid homeostasis, stimulation of
neuroprogenitor cells after brain injury [3], and induction of cell
senescence in central nervous system [4]. Even if its impact on
oncogenesis is not clear, it has been described as a putative TSG
in several cancers including esophageal squamous cell carcino-
ma [5-9], prostate cancer [10], colo-rectal cancer and glioma
[8,11]. ECRG4 expression was associated with better survival in
esophageal [6] and prostate [10] carcinomas, and with
inhibition of cell proliferationa n dm i g r a t i o ni ne s o p h a g e a l
cancer [7-9], colorectal cancer and glioma [9,11]. Surprisingly,
no data are available regarding ECRG4 expression in breast
cancer.
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27656Here, we have analyzed the expression of ECRG4 in a large
series of breast cancers profiled using DNA microarrays and its
correlation with histo-clinical features and survival.
Materials and Methods
Ethics statement
The study was approved by our institutional review board: the
Institut Paoli Calmettes (IPC) ‘‘Comite ´ d’Orientation Strate ´gi-
que’’. Each patient gave a written informed consent for research
use.
Gene expression data
To determine ECRG4 mRNA expression in breast cancer and
normal breast, we first analyzed gene expression data generated by
our laboratory (IPC, Marseille, France) from cancer and normal
mammary samples. Tumor tissues were from 353 patients with
invasive adenocarcinoma who underwent initial surgery at IPC
between 1987 and 2007. Samples were macrodissected and frozen
in liquid nitrogen within 30 min of surgical removal. All profiled
specimens contained more than 60% of cancer cells (as assessed
before RNA extraction using frozen sections adjacent to the
profiled samples). After surgery, patients received an adjuvant
multimodal treatment according to standard guidelines. Extraction
of nucleic acids from frozen samples was done by using guanidium
isothiocynanate and cesium chloride gradient as described
previously [12]. RNA integrity was controled on Agilent
Bioanalyzer (Agilent TechnologiesH, La Jolla, CA, USA). We
had also profiled 4 normal breast (NB) tissue samples, which
represented 1 pool of 4 samples from 4 healthy women (reduction
mammoplasty), and 3 commercial pools of respectively 1, 2 and 4
normal breast RNA (Clontech, Palo Alto, CA). Expression profiles
had been established for these 353 cancers and 4 NB pools with
Affymetrix U133 Plus 2.0 human microarrays (AffymetrixH, Santa
Clara, CA, USA) as previously described [13]. All data are
MIAME compliant and the raw data have been deposited in the
MIAME-compliant GEO database (GSE23720, GSE21653,
GSE17987 and GSE31448).Data were analyzed by the Robust
Multichip Average method [14] in R using Bioconductor and
associated packages. ERCG4 expression was measured by
analyzing the sole Affymetrix probe set present, ID 223623_at,
the specificity of which was verified using the NCBI program
BLASTN 2.2.25+ (Table S1). Before analysis, expression level for
each tumor was centered by the average expression levels of the
four NB samples. Data were then log2-transformed for analysis
and display.
To examine the correlation between ECRG4 mRNA expression
and histo-clinical features of tumors in a large series, we pooled our
data set with 5 publicly available data sets comprising at least one
probe set representing ECRG4. These sets were collected from the
National Center for Biotechnology Information (NCBI)/Genbank
GEO database (series entry GSE1456 [15], GSE3494 [16],
Table 1. Histo-clinical characteristics of the 1,387 breast
cancer patients.
Characteristics N (%)
Sex
Female 1387 (100%)
Age (years)
#50 380 (37%)
.50 637 (63%)
Histological type
DUC 509 (82%)
LOB 32 (5%)
MIX 28 (4%)
MED 24 (4%)
Other 31 (5%)
Clinical stage
I 86 (29%)
II 138 (46%)
III 55 (19%)
IV 18 (6%)
pN
Negative 460 (43%)
Positive 619 (57%)
pT
pT1 320 (31%)
pT2 517 (50%)
pT3 169 (16%)
pT4 37 (3%)
SBR Grade
1 172 (13%)
2 475 (37%)
3 631 (49%)
ER (IHC)
Negative 499 (44%)
Positive 624 (56%)
PR (IHC)
Negative 364 (50%)
Positive 363 (50%)
ERBB2 (IHC)
Negative 261 (72%)
Positive 100 (28%)
Relapse*
No 755 (67%)
Yes 365 (33%)
5-year DFS* 68%
Death*
No 544 (73%)
Yes 199 (27%)
5-year OS* 80%
pCR
No 96 (58%)
Yes 70 (42%)
N, number of cases available; DUC, ductal carcinoma, LOB, lobular carcinoma,
MIX, mixed; MED, medullary carcinoma; pN, pathological lymph node
involvement; pT, pathological tumor size; IHC, immunohistochemistry; ER,
estrogen receptor; PR, progesterone receptor; DFS, disease-free survival; OS,
overall survival;
*, non-stage IV patients; pCR, pathological complete response to primary
chemotherapy defined as disappearance of the invasive component of the
primary tumor after treatment.
doi:10.1371/journal.pone.0027656.t001
Table 1. Cont.
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address https://genome.unc.edu/pubsup/breastGEO/(Table S1).
This resulted in a total of 1,387 invasive breast cancers with
ECRG4 mRNA expression and histo-clinical data available for
meta-analysis (Table 1). To be comparable across data sets and
to exclude bias from population heterogeneity, ECRG4 expression
levels were standardized within each data set using the luminal A
population as reference. The intrinsic molecular subtypes of
tumors were defined as previously described [19] using the Single
Sample Predictor (SSP) classifier based on a list of 306 intrinsic
genes [20].
To attempt exploring the biological pathways linked to ECRG4
expression, we identified genes correlated with ECRG4 mRNA
levels using Significance Analysis of Microarrays (SAM) [21] in
our own data set. We compared the 50 tumors with the highest
expression level to the 50 tumors with the lowest one. We applied
a D-value of 2.4 and a false discovery rate of 0.1%. Ontology
analysis of the resulting gene list was performed using Ingenuity
Pathway Analysis (IPA) software (Redwood City, CA, USA) [22].
We only studied pathways with at least 10 genes represented, and
with a p-value lower than 0.01.
Array-comparative genomic hybridization data
We analyzed data on genomic imbalances for 247 out of the 353
breast tumors, generated by array-comparative genomic hybrid-
ization (aCGH) using 244K CGH Microarrays (Hu-244A, Agilent
Technologies) as previously described [12]. A pool of 13 normal
male DNA had been used as reference. Extraction of data (log2
ratio) was done from CGH Analytics, whereas normalized and
filtered log2 ratio was obtained from ‘‘Feature Extraction’’
software (Agilent Technologies). The ECRG4 locus at 2q12.2 was
analyzed and copy number changes were characterized as
reported previously [12]. Three probes (A_16_P15770886,
A_14_P201475, A_14_P138926) matched the ECRG4 gene on
our Agilent chips.
Statistical analyses
Comparison of mean ECRG4 mRNA expression level according
to classical histo-clinical factors was done using Student t-test (2
variables) or one-way analysis of variance (ANOVA; more than 2
variables). Disease-free survival (DFS) was calculated from the date
of diagnosis until date of relapse or death when date of relapse was
Figure 1. mRNA expression of ECRG4 in breast cancer. (A) Thumbnail of the hierarchical clustering of the 353 breast cancers and 4 NB samples
(columns) and the 12,304 most variable genes (rows). According to a log2 pseudocolor scale (bottom), red indicates a high level of mRNA expression
compared to the median value across all samples, whereas green indicates a low level of expression. The magnitude of deviation from the median is
represented by the colour saturation. The dendrogram of samples (above matrixes) represents overall similarities in gene expression profiles and is
zoomed in B. Green branches indicate the 4 NB samples. To the right of the color matrix, are represented some biologically relevant gene clusters.
The extra-cellular matrix (ECM)-related cluster, which includes ECRG4, is detailed in C. (B) Samples dendogram. Green branches indicate the 4 NB
samples. Under the dendogram are reported some histo-clinical tumor features colored as below: ER IHC status (white, negative, and black, positive);
ERBB2 IHC status (white, negative, and black, positive); SBR Grade (white, 1, grey, 2; and black, 3molecular subtypes (dark blue, luminal A, light blue,
Luminal B, pink, ERBB2, red, basal-like, and green, normal-like). Some molecular features regarding ECRG4 are represented below: mRNA expression
level (median-centered and color-coded as in A), expression status as compared to NB (overexpression, black, neutral, grey, and underexpression,
white), and aCGH-based copy number alteration (CNA: gain, black, neutral, grey, and loss, white). (C) Details of the genes belonging to the ECM gene
cluster.
doi:10.1371/journal.pone.0027656.g001
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diagnosis to the date of death from breast cancer. Follow-up was
measured from the date of diagnosis to the date of last news for
patients without event. Survivals were calculated using the
Kaplan-Meier method and curves were compared with the log-
rank test. Univariate and multivariate survival analyses were done
using Cox regression analysis (Wald test). Variables tested in
univariate analyses included patients’ age at time of diagnosis (#50
years vs .50), pathological tumor size (pT: pT1 vs pT2-4),
pathological axillary lymph node status (pN: negative vs positive),
pathological grade (I vs 2-3), immunohistochemical (IHC) estrogen
receptor (ER), progesterone receptor (PR), and ERBB2 status
(negative vs positive), histological type, and ECRG4 expression
(continuous value). Variables with a p-value ,0.01 in univariate
analysis were tested in multivariate analysis. All statistical tests
were two-sided at the 5% level of significance. Statistical analysis
was done using the survival package (version 2.30) in the R
software (version 2.9.1; http://www.cran.r-project.org/). We
followed the reporting REcommendations for tumor MARKer
prognostic studies (REMARK criteria) [23].
Results
ECRG4 mRNA expression in breast cancer
We first analyzed expression data generated in our laboratory
by using Affymetrix microarrays from 357 mammary samples
including 353 pre-treatment primary cancers and 4 NB samples.
Compared to NB, 333 tumors (94.3%) showed underexpression
(defined by ratio T/NB #0.66), whereas only 5 tumors (1.4%)
showed overexpression (ratio T/NB .1.5), and 15 (4.2%) showed
similar expression (0.66, ratio T/NB #1.5). Whole-genome
hierarchical clustering showed that ECRG4 was located within an
archetypal extracellular matrix-related gene cluster, including for
example several collagen, integrin and metalloproteinase genes
(Figure 1).
Data from aCGH were available for 247 of the 353 tumor
samples from our institution, allowing us to analyze the ECRG4
locus at 2q12.2. Loss/deletion of this region has not been reported
as recurrent in breast cancer. In our series, a DNA copy number
alteration (1.5 fold change as compared to normal DNA) was
present in 10 tumors (10%) for the gains, and 44 (18%) for the
losses, and absent in 179 tumors (72%). There was no significant
difference in the frequency of ECRG4 copy number alteration
between the molecular subtypes (p=0.08, Fisher’s exact test).
Regarding the DNA/RNA correlations, 44 out of the 44 (100%)
tumors with DNA loss showed mRNA underexpression; however,
23 out of the 24 (96%) tumors with DNA gain and 172 out of the
179 (96%) tumors with ‘‘normal’’ DNA copy number also showed
underexpression, suggesting that ECRG4 loss is not the main
mechanism of underexpression in breast cancer.
ECRG4 expression and histo-clinical correlations
We searched for correlations between ECRG4 mRNA expres-
sion and histo-clinical features of tumors in a large data set of
1,387 invasive breast cancers, including our series and 5 public
microarray data sets. Of note, the pattern of expression was
observed homogeneously through all the data sets (Figure S1),
and more than 90% of tumor samples showed ECRG4 under-
expression as compared to NB in each data set and in the pooled
data set. As shown in Table 2, ECRG4 expression was
significantly (t-test) associated with age inferior to 50 years, early
clinical stage, small pathological tumor size, absence of axillary
lymph node involvement, low tumor grade, and histological type
(being the highest in lobular type and the lowest in medullary
Table 2. Correlation of ECRG4 expression and histoclinical
features (n=1,387).
Characteristics (N)
mean ECRG4 expression
(compared to NB) p-value
Age (years) 6,17E-03
#50 (380) 22,6
.50 (637) 22,81
Histological type 7,72E-03
DUC (509) 22,71
LOB (32) 22,28
MIX (28) 22,54
MED (24) 23,45
Other (31) 22,69
Clinical stage 1,64E-03
I (86) 22,47
II-IV (211) 22,94
pN 8,69E-03
Negative (460) 22,6
Positive (619) 22,79
pT 1,30E-03
pT1 (320) 22,53
pT2-4 (723) 22,79
ER (IHC) 0,47
negative (499) 22,74
positive (624) 22,69
PR (IHC) 0,11
negative (364) 22,77
positive (363) 22,62
ERBB2 (IHC) 0,32
negative (261) 22,75
positive (100) 22,88
SBR grade 1,55E-10
1 (172) 22,25
2 (475) 22,56
3 (631) 22,88
SSP molecular subtype 8,25E-72
Luminal A (419) 22,62
Luminal B (188) 23,33
Basal (375) 22,76
ERBB2 (168) 23,28
Normal-like (237) 21,57
pCR 0,53
No 22,6
Yes 22,47
N, number of samples with data available; ILC, invasive lobular carcinoma; MED,
medullary carcinoma; IDC, invasive ductal carcinoma; pN, pathological lymph
node involvement; pT, pathological tumor size; IHC, immunohistochemistry; ER,
estrogen receptor; PR, progesterone receptor; SBR, Scarff, Bloom and
Richardson; SSP, single sample predictor [20]; pCR, pathological complete
response to primary chemotherapy defined as disappearance of the invasive
component of the primary tumor after treatment. HR, hazard ratio; 95CI,95%
confidence interval.
doi:10.1371/journal.pone.0027656.t002
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ER, PR and ERBB2. Regarding the molecular subtypes, we
observed higher ECRG4 expression in normal-like cases
(p=8.25E-72, one-way ANOVA, Figure 2), consistent with a
higher expression in NB.
We then examined the prognostic value of ECRG4 expression in
non-stage IV patients. Regarding DFS, the follow-up was available
for 1,120 patients (68% 5-year DFS): 365 patients experienced a
relapse of their disease after a median time of 24 months from
diagnosis, and 755 remained relapse-free with a median follow-up
of 70 months. In univariate analysis (Table 3), high ERCG4
expression (HR=0.84 [0.76-0.92]; p=0.0002), as well as age
superior to 50 years, node-negative status, small tumor size (pT1),
low grade (SBR 1), positive ER and PR status, and negative
ERBB2 status, were associated with a better DFS. Figure 3A
shows the Kaplan-Meier curves for DFS according to ECRG4
expression. However, in multivariate analysis, only ECRG4
expression maintained its prognostic value (p=0.049, Table 3).
Regarding OS, data were available for 743 patients (80% 5-year
OS): 199 of them died of breast cancer after a median time of 46
months from diagnosis, and 544 were alive with a median follow-
up of 94 months. In univariate analysis (Table 4), high ECRG4
expression was associated with longer OS (HR=0.72 [0.63-0.83],
p=4.46E-06), as were node-negative status, small tumor size
(pT1), low grade (SBR I), positive ER and PR status, and negative
ERBB2 status. The OS Kaplan-Meier curves according to ECRG4
expression are shown in Figure 3B. Here too in multivariate
analysis, ECRG4 expression was the only significant parameter
with an independent prognostic value (p=0.035, Table 4),
whereas all other classical prognostic factors (age, pathological
tumor size, pathological lymph node involvement, pathological
grade, ER, PR and ERBB2 expression) lost their prognostic value.
Finally, we assessed the correlation between ECRG4 expression
and the response to neo-adjuvant chemotherapy in early breast
cancer. We analyzed expression data from 166 cases (41 from our
own series and 125 from [19]) pre-operatively treated with an
anthracycline or an anthracycline/taxane-based regimen. Out of
them, 70 displayed pCR after chemotherapy, and 96 did not. ECRG4
expression was not correlated with pCR (p=0.36, t-test; Table 2).
Biological pathways associated with ECRG4 expression
Using Significance Analysis of Microarrays, we identified 891
genes differentially expressed between the 50 tumors with the
lowest ECRG4 expression and the 50 ones with highest expression.
Most of these genes (n=800) were overexpressed in the tumors of
the last group. Ontology analysis of these 891 genes revealed that
ECRG4 overexpression was correlated with expression of genes
associated with axon guidance, protein kinase A signaling, integrin
signaling, endocytosis, ephrin signaling, CXCR4 signaling, and
the Wnt/b-catenin pathway (Table S2).
Discussion
The ECRG4 gene, officially named C2ORF40, is highly
conserved in vertebrates, not in other eukaryotic species,
suggesting an important role in vertebrate organisms. Although
identified many years ago, the function of the protein encoded by
this gene remains unclear, but recent data revealed a potential
TSG role in different cancers. To our knowledge, our study is the
first one analysing ECRG4 in normal and cancer mammary tissues.
Through the analysis of more than 350 breast cancers, we show
that ECRG4 is underexpressed in 94% of tumors. Frequent down-
regulation has also been reported in cell lines and clinical tissue
samples of esophagal, colo-rectal, and prostate carcinomas, and
gliomas. Of note, all breast cancer cell lines profiled in our
laboratory also showed very low expression of ECRG4 when
compared to HME1, a non-tumorigenic mammary cell line
derived from mammoplasty (data not shown). This underexpres-
sion of mRNA may be due to genetic or epigenetic mechanisms, as
well as decreased mRNA stability. Here, we show that DNA loss,
although relatively frequent (18%), cannot explain the high
frequency of downregulation. We did not analyze mutations and
DNA methylation. No ECRG4 mutation has been reported in
cancers [7,24]. Epigenetic alterations of the genome such as DNA
promoter methylation play an important role in tumorigenesis of
various human cancers by silencing TSG [25]. In breast cancer,
multiple TSG are hypermethylated and downregulated, including
for examples BRCA1, RASSF1A, p16, FHIT, and CDH1 [26].
Promoter methylation can also be observed in normal breast tissue
Figure 2. mRNA expression of ECRG4 according to breast cancer molecular subtypes. ECRG4 expression across 1,387 breast cancer samples
was examined according to molecular subtypes. Box plots of ECRG4 expression are shown according to basal, ERBB2, luminal A, luminal B, and
normal-like subtypes. Expression values are NB-centered. The horizontal black line represents the level of expression of ECRG4 in normal breast (NB)
tissue. Differences in ECRG4 expression levels between the subtypes were tested for significance using one-way ANOVA. For each box plot, median
and ranges are indicated.
doi:10.1371/journal.pone.0027656.g002
ERCG4 Is Down-Regulated in Breast Cancer
PLoS ONE | www.plosone.org 5 November 2011 | Volume 6 | Issue 11 | e27656adjacent to invasive carcinomas [27]. The ECRG4 5-prime UTR
contains multiple cis-acting elements and 16 CpG islands. In
esophagal, colo-rectal, and prostate carcinomas, and gliomas,
promoter methylation is the main mechanism of ECRG4 silencing,
and treatment with demethylating agents restore gene expression
[7]. Promoter methylation was recently evidenced in the MCF7
breast cancer cell line [11]. However, this is a single example,
which calls for methylation analysis of more cancer cell lines and
tissue samples since it is likely that promoter methylation
contributes for silencing ECRG4 in breast cancer.
The tumor suppressor function of ECRG4 [28] and the cellular
consequences of its silencing remain to be investigated in breast
cancer. In cell lines of esophageal [7–9] and colo-rectal cancer
[11] and glioma [8], the overexpression of ECRG4 inhibits cell
proliferation by blocking the G1/S transition of cell cycle, through
increase of p21 and p53 protein expression. The inhibition of
proliferation was confirmed in vivo after injection of ECRG4-
transfected esophageal cancer cell lines into athymic nude mice,
which led to slower tumor growth [7]. Another in vitro effect of
ECRG4 overexpression is the inhibition of cell migration and
invasion in cell lines from esophageal carcinoma and glioma [8].
Meta-analysis of histo-clinical correlations in our series of more
than 1.000 cases further reinforced the idea that ECRG4 is a
candidate TSG in breast cancer. Consistent with growth and
Figure 3. Disease-free and overall survivals according to ERCG4 mRNA expression. (A) Kaplan-Meier DFS curves in patients with high and
low expression (cut-off defined with Cox proportional-hazards regression model built on the IPC data). The respective 5-year DFS are 73 and 63%. (B)
Kaplan-Meier OS curves (the legend is similar to A). The respective 5-year DFS are 88 and 74%.
doi:10.1371/journal.pone.0027656.g003
Table 3. Disease-free survival (DFS), Cox regression analyses.
Univariate Multivariate
N HR [95CI] p-value N HR [95CI] p-value
ECRG4 1120 0.84 [0.76–0.92] 0.0002 254 0.82 [0.67–0.99] 0.049
Age .50 vs #50 years 958 0.78 [0.63–0.98] 0.03
Histology 472 0.151
ILC vs IDC 1.22 [0.69–2.15]
MED vs IDC 0.50 [0.20–1.22]
Mixed vs IDC 0.46 [0.22–1]
Other vs IDC 0.94 [0.48–1.85]
pN positive vs negative 930 2.21 [1.74–2.80] 5.27 E-11 254 1.22 [0.79–1.89] 0.37
pT pT2-3 vs pT1 879 2.56 [1.93–3.40] 6.79 E-11 254 1.28 [0.79–2.05] 0.31
SBR grade 2-3 vs 1 1075 2.80 [1.92–4.07] 8.29 E-08 254 1.37 [0.71–2.67] 0.35
ER positive vs negative 943 0.64 [0.51–0.80] 9.42 E-05 254 0.86 [0.40–1.86] 0.71
PR positive vs negative 572 0.67 [0.50–0.88] 0.004 254 1.02 [0.49–2.12] 0.97
ERBB2 positive vs negative 310 2.32 [1.58–3.39] 1.64 E-05 254 1.02 [0.56–1.86] 0.94
N, number of samples with data available; ILC, invasive lobular carcinoma; MED, medullary carcinoma; IDC, invasive ductal carcinoma; pT, pathological tumor size; pN,
pathological lymph node involvement; ER, estrogen receptor; PR, progesterone receptor; SBR, Scarff, Bloom and Richardson; HR, hazard ratio;95CI,95% confidence
interval.
doi:10.1371/journal.pone.0027656.t003
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between mRNA expression, the progression stage, and the tumor
grade, with higher expression in early stage, in small tumors, in
node-negative cases, and in low grade tumors. Similar observation
was reported in smaller series of esophageal cancer at the mRNA
[6] and protein [7] levels. Importantly, ECRG4 expression was
associated with DFS and OS in both uni- and multivariate
analyses. The patients whose tumor expressed higher levels of
ECRG4 mRNA survived longer and without relapse than those
with lower levels. A similar correlation was reported in small series
of esophageal [6–7] and prostate carcinomas [10].
In conclusion, we report the first large-scale analysis of ECRG4
expression in breast cancer. Our results suggest that ECRG4 is a
candidate TSG in breast cancer. Based on our observations and
literature data, we speculate that ECRG4 underexpression confers
growth and migration advantages to breast cancers, leading to poor
prognosis. Functional analyses are warranted to confirm this TSG
role in mammary oncogenesis. Potential clinical applications are
therapeutic and prognostic. Whatever the mechanism of silencing,
restoring ECRG4 expression in the tumor, either by epigenetic
therapy or application of recombinant protein, may represent a
promising novel therapeutic approach in breastcancer. Furthermore,
ECRG4 expression may help improve the prognostication of disease.
Supporting Information
Figure S1 mRNA expression of ECRG4 in each data set,
and in the pooled data set. Box plots of ECRG4 expression are
shown for each data set. Expression values are NB-centered. The
horizontal black line represents the level of expression of ECRG4 in
the NB sample. For each box plot, median and ranges are
indicated. IPC, Institut Paoli Calmettes, UNC, University of
North Carolina; n, number of samples analyzed. No significant
difference was observed between the different distributions
(Anova, p.0.05).
(PPT)
Table S1 Description of the breast cancer data sets
(XLS)
Table S2 Canonical pathways associated with ECRG4
expression
(XLS)
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